Compare DCX & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCX | ALZN |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 4.6M |
| IPO Year | 2022 | 2021 |
| Metric | DCX | ALZN |
|---|---|---|
| Price | $0.90 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 226.0K | 42.3K |
| Earning Date | 05-14-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.84 |
| 52 Week High | $5.68 | $2.68 |
| Indicator | DCX | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 62.43 |
| Support Level | $0.94 | $1.04 |
| Resistance Level | $1.32 | $2.22 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 42.41 | 95.24 |
Digital Currency X Technology Inc, formerly Chijet Motor Company Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.